Alembic gains FDA tentative approval for generic Latisse
Alembic Pharmaceuticals has received tentative approval from the Food & Drug Administration for bimatoprost ophthalmic solution 0.03% for the treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
The product is the generic of Allergan’s Latisse ophthalmic solution 0.03%
Bimatoprost ophthalmic solution's market size is estimated at $63 million for the 12 months ended December 2017, according to IQVIA.
The product is the generic of Allergan’s Latisse ophthalmic solution 0.03%
Bimatoprost ophthalmic solution's market size is estimated at $63 million for the 12 months ended December 2017, according to IQVIA.